Why the study?
Does self-management of oral anticoagulation improve the percentage of time spent within the therapeutic range in patients receiving long-term warfarin?
Does self-management of oral anticoagulation improve the percentage of time spent within the therapeutic range in patients receiving long-term warfarin?
Self-management of oral anticoagulation is safe and achieves similar time in therapeutic range compared to routine care, with potential benefits for patients with initially poor control.
Answers are grounded in this paper and cite their sources.
Self-management achieves similar TTR and safety to routine care; confirms feasibility as an alternative without overall superiority in unselected patients.
OBJECTIVE: To determine the clinical effectiveness of self management compared with routine care in patients on long term oral anticoagulants. DESIGN: Multicentre open randomised controlled trial. SETTING: Midlands region of the UK. PARTICIPANTS: 617 patients aged over 18 and receiving warfarin randomised to intervention (n = 337) and routine care (n = from 2470 invited; 193/337 (57%) completed the 12 month intervention. INTERVENTION: Intervention patients used a point of care device to measure international normalised ratio twice a week and a simple dosing chart to interpret their dose of warfarin. MAIN OUTCOME MEASURE: Percentage of time spent within the therapeutic range of international normalised ratio. RESULTS: No significant differences were found in percentage of time in the therapeutic range between self management and routine care (70% v 68%). Self managed patients with poor control before the study showed an improvement in control that was not seen in the routine care group. Nine patients (2.8/100 patient years) had serious adverse events in the self managed group, compared with seven (2.7/100 patient years) in the routine care arm (chi2(df = 1) = 0.02, P = 0.89). CONCLUSION: With appropriate training, self management is safe and reliable for a sizeable proportion of patients receiving oral anticoagulation treatment. It may improve the time spent the therapeutic range for patients with initially poor control. Trial registration ISRCTN 19313375.
No takes yet. Share an insight, caveat, or question.
Fitzmaurice et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: